Mp70-11 reverse of docetaxel resistance in prostate cancer via notch signaling inhibition

Chemotherapeutic Docetaxel (Doc) is the standard of care for the hormone resistant prostate cancer (HRPC). However, many HRPC patients do not respond to Doc chemotherapy in a long-term treatment because the cancerous tissue acquires resistance to Doc treatment. The molecular mechanism underlying the development of Doc resistance in HRPC remains unclear.

Source: The Journal of Urology - April 1, 2018 Category: Urology & Nephrology Authors: Qiu Shi, Xiang Tu, Qiang Wei, Lu Yang Tags: Prostate Cancer: Basic Research & Pathophysiology III Source Type: research